The Wall Street Journal:Navidea Biopharmaceuticals Announces Positive Initial Results in Single-Center Cohort from Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment Navidea Biopharmaceuticals Announces Positive Initial Results in Single-Center Cohort from Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment